Intervention
Semaglutide
ClinicalTrials.gov intervention label
Clinical trials
60 shownA Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to SemaglutideNCT07668414 · 2026-09-22
RECRUITINGA First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or ObesityNCT07767175 · 2026-08-12
RECRUITINGResearch Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body WeightNCT07770841 · 2026-08-12
RECRUITINGEffects of Semaglutide on Brain Dopamine Responses to Food Cues in Adults With Obesity and Food Addiction TendenciesNCT07732426 · 2026-07-15
RECRUITINGA Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes MellitusNCT07662213 · 2026-07-06
RECRUITINGA Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 DiabetesNCT07668388 · 2026-06-22
RECRUITINGA Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414 · 2026-05-21
RECRUITINGInvestigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With DiabetesNCT07428746 · 2026-05-07
RECRUITINGA Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 DiabetesNCT07415954 · 2026-04-17
RECRUITINGUnderstanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)NCT07527195 · 2026-04-10
RECRUITINGSide-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 DiabetesNCT07317115 · 2026-03-18
RECRUITINGSemaglutide for Smoking Cessation in Patients With DiabetesNCT07059377 · 2026-02-13
RECRUITINGEffect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.NCT07242534 · 2026-01-19
RECRUITINGA Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285 · 2026-01-08
RECRUITINGExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)NCT07225816 · 2025-11-07
RECRUITINGMetabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT TrialNCT07202247 · 2025-11-05
RECRUITINGGlucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With ObesityNCT07091500 · 2025-08-11
RECRUITINGA Study of BGM0504 in Participants With Type 2 Diabetes in IndonesiaNCT07064486 · 2025-07-04
RECRUITINGA Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)NCT07101939 · 2025-06-23
RECRUITINGThe Role of the Amylin Analogue Cagrilintide in Bone MetabolismNCT07010432 · 2025-06-12
RECRUITINGSemaglutide and Tirzepatide for Genetic Aging Delay in Adults With ObesityNCT07293325 · 2025-06-02
RECRUITINGSemaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial FibrillationNCT06499857 · 2025-04-14
RECRUITINGA Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney DiseaseNCT06717698 · 2024-12-02
RECRUITINGObesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2NCT06396416 · 2024-09-26
RECRUITINGMultifactorial Intervention to Reduce Cardiovascular Disease in Type 1 DiabetesNCT06082063 · 2024-07-01
RECRUITINGImpact of Semaglutide on Tobacco Use and Related Health BehaviorsNCT06986993 · 2024-07-01
RECRUITINGTrial of Semaglutide for Diabetic Kidney Disease in Type 1 DiabetesNCT05822609 · 2024-04-05
RECRUITINGCOMMETS- Combination MCI Metabolic SyndromeNCT06072963 · 2024-01-30
RECRUITINGSit Less, Interact and Move More (SLIMM) 2 StudyNCT05173714 · 2021-12-01
RECRUITINGPharmacogenetics of the Response to GLP-1 in Mexican-Americans With PrediabetesNCT05119179 · 2021-11-22
RECRUITINGGLP-1 RA for Stage 1 Type 1 DiabetesNCT07430332 · 2027-09-01
NOT_YET_RECRUITINGRegulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in KoreaNCT05714683 · 2027-01-31
NOT_YET_RECRUITINGPatient-centred Intervention With Virtual Support for Obesity and Kidney Transplant AccessNCT07858331 · 2027-01-01
NOT_YET_RECRUITINGGLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver DiseaseNCT06546384 · 2026-11-01
NOT_YET_RECRUITINGGLP-1 Plus Lifestyle for Overall Wellness: Find Your Way ForwardNCT06977438 · 2026-10-15
NOT_YET_RECRUITINGA Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or ObesityNCT07845500 · 2026-10-01
NOT_YET_RECRUITINGA Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide MedicationNCT07855133 · 2026-09-30
NOT_YET_RECRUITINGA Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body WeightNCT07845578 · 2026-09-25
NOT_YET_RECRUITINGBALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or ObesityNCT07622810 · 2026-09-01
NOT_YET_RECRUITINGStudy on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With AlbuminuriaNCT07849348 · 2026-09-01
NOT_YET_RECRUITINGSemaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase InhibitorsNCT07769047 · 2026-09-01
NOT_YET_RECRUITINGBALANCE-DM2 Study of Bofanglutide in Adults With Type 2 DiabetesNCT07628985 · 2026-09-01
NOT_YET_RECRUITINGReal-World Patient and Physician Experience With Semaglutide Across Six Emerging MarketsNCT07850765 · 2026-08-28
COMPLETEDTesting the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.NCT07411378 · 2026-07-01
NOT_YET_RECRUITINGA Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With ObesityNCT07639021 · 2026-06-09
ACTIVE_NOT_RECRUITINGEfficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DMNCT07570810 · 2026-06-01
NOT_YET_RECRUITINGAMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightNCT07400107 · 2026-05-20
NOT_YET_RECRUITINGWeight Loss in Adults Using Semaglutide (Real-world Study)NCT07627074 · 2026-05-12
COMPLETEDRapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)NCT07547878 · 2026-04-30
NOT_YET_RECRUITINGGLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort StudyNCT07588984 · 2026-04-30
NOT_YET_RECRUITINGCombatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1NCT07554417 · 2026-04-06
NOT_YET_RECRUITINGMIST (Metabolic Intervention With Semaglutide and THR-β Therapy) TrialNCT07505303 · 2026-03-23
ACTIVE_NOT_RECRUITINGTirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.NCT07619508 · 2026-02-10
COMPLETEDRegulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in KoreaNCT05689372 · 2026-02-02
ENROLLING_BY_INVITATIONINcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)NCT07417618 · 2026-01-27
COMPLETEDInjectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular RiskNCT07619495 · 2026-01-20
COMPLETEDPhase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes MellitusNCT07187856 · 2026-01-01
NOT_YET_RECRUITINGEfficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have DiabetesNCT07284979 · 2025-12-30
ACTIVE_NOT_RECRUITINGEffect of Semaglutide and Tirzepatide Combined With Exercise in ObesityNCT07319975 · 2025-12-29
NOT_YET_RECRUITINGWEgovy Real World Assessment of Weight Loss in KoreaNCT07280221 · 2025-11-10
ENROLLING_BY_INVITATIONCommon conditions
Obesity85Diabetes Mellitus, Type 262Overweight36Type 2 Diabetes23Diabetes10Type 2 Diabetes Mellitus7Chronic Kidney Disease6Obesity & Overweight5Healthy Volunteers4Non-Alcoholic Fatty Liver Disease4Overweight or Obesity4Heart Failure3Muscle Loss3Type 1 Diabetes3Atrial Fibrillation2Chronic Kidney Diseases2Healthy2HFpEF - Heart Failure With Preserved Ejection Fraction2Idiopathic Intracranial Hypertension2Metabolism and Nutrition Disorder2Obesity or Overweight2Type 2 Diabetes (T2DM)2Type 2 Diabetes Mellitus (T2DM)2Weight Loss2Abdominal Fat1
Leading sponsors
Novo Nordisk A/S113Brigham and Women's Hospital9Eli Lilly and Company7Mayo Clinic4AstraZeneca3Boehringer Ingelheim3University Medical Centre Ljubljana3Carnot Laboratories2Pfizer2University of Minnesota2Washington University School of Medicine2Actimed Therapeutics Ltd1Ali Aminian1Baylor Research Institute1Biophytis1
Trial status mix
COMPLETED118
RECRUITING30
ACTIVE_NOT_RECRUITING27
NOT_YET_RECRUITING22
UNKNOWN11
WITHDRAWN6
ENROLLING_BY_INVITATION3
TERMINATED2
SUSPENDED1
Phase mix
PHASE377
PHASE236
PHASE131
PHASE430
NA12
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.